E9 - Creating a Coding and Reimbursement Framework for Emerging Psychedelic Therapies

Wednesday, May 3, 2023

10:30 AM – 11:30 AM

Location: 515 A, Level 2, LACC

None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Relias, LLC and National Council for Mental Wellbeing guarantee this educational conference is free from bias.

Workshop Presenter(s)

Steve Levine, MD

SVP, Patient Access & Medical Affairs
COMPASS Pathways
Princeton, New Jersey

Slides

Several potentially paradigm-shifting new treatments that combine a psychedelic medication with support from therapists are in late-stage development for mental health indications with high unmet needs. Should they receive FDA-approval, the challenge will be achieving equitable access for those who may benefit through broad reimbursement across all payer types. We will highlight unmet needs in mental health treatment; provide an overview of psychedelic therapies in development through FDA clinical trials for a range of indications; demystify the complex system of codes used for reimbursement across treatment settings; describe the development, application and implementation of new CPT codes; and analyze the evidence for psychedelic therapies in development through FDA clinical trials for a range of indications

Learning Objectives:

Analyze the evidence for psychedelic therapies in development through FDA clinical trials for a range of indications.
Define the system of codes used for healthcare reimbursement across treatment settings (HCPCS/CPT).
Describe the development, application and implementation of new CPT codes.